Corporate News

Pentracor GmbH: Blutwäscheverfahren bei akutem Herzinfarkt und Covid-19 erfolgreich

Pentracor GmbH: Fristgerechte Zinszahlung der Anleihe

Hennigsdorf, 2. Mai 2022 – Das Medizintechnikunternehmen Pentracor GmbH (Wandelanleihe ISIN: DE 000 A289XB9, WKN: A289XB) mit Sitz im brandenburgischen Hennigsdorf gibt bekannt: Die Zinszahlungen für die vorbezeichnete Anleihe werden auch im Geschäftsjahr 2022 fristgerecht am 29. Mai in vereinbarter Höhe an die Anleihenehmer erfolgen.

Rainer Mohr is the new CFO of Pentracor GmbH since the beginning of the year

Hennigsdorf, January 20, 2022 - The medical technology company Pentracor GmbH from Hennigsdorf (convertible bond ISIN: DE000A289XB9, WKN: A289XB) has employed Rainer Mohr as a new Chief Financial Officer (CFO) since January 1, 2022.

In this function, Rainer Mohr controls and implements the strategic development of the company in all commercial and financial areas in close coordination and cooperation with the management of Pentracor.

Pentracor GmbH wins most important business award of the state of Brandenburg

Hennigsdorf, 15. November 2021 - The medical technology company Pentracor GmbH from Hennigsdorf has won the "Zukunftspreis Brandenburg" 2021, the most important business prize in the state. The high-caliber, 16-member jury praised in particular the company's medical innovative strength, regional networking with clinics and science, and attention from international research. The award ceremony took place on November 12 at the Airport Center Berlin Schönefeld in the presence of Minister President Dr. Dietmar Woidke.

Pentracor GmbH with good third quarter 2021 and sales of 0.32 million euros - Pandemic continues to influence development

Hennigsdorf, 27.10.2021 - With 0.32 million euros, the Brandenburg-based medical technology company Pentracor (convertible bond ISIN: DE000A289XB9, WKN: A289XB) achieved a new record in sales in its still young history in the third quarter of 2021. As expected, half-year sales amounted to EUR 0.57 million. In the first nine months of 2021, Pentracor GmbH recorded significantly higher sales revenue of around EUR 0.89 million than in the full year 2020 (EUR 0.35 million).

Pentracor GmbH publishes 2020 financial statements and makes good progress in the first half of 2021

Hennigsdorf, July 28, 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin has published its 2020 annual financial statements. The financial year was characterized by the roll-out of the PentraSorb® CRP medical product developed and certified by the company, as well as the initiation and execution of clinical studies to increase acceptance for CRP apheresis in the treatment of diseases associated with acute inflammation such as myocardial infarction.

Broad media coverage of Pentracor's promising blood wash therapy for COVID-19 patients

Hennigsdorf, 18.05.2021 - Today, the German TV station ZDF reported in detail about the promising CRP apheresis for COVID-19 patients from the medical technology company Pentracor GmbH based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB). At Berlin's Havelhöhe Community Hospital, Pentracor's new therapeutic extracorporeal treatment method is now being used with great success on many severely ill COVID-19 patients.

Promising treatment success in patients with severe COVID-19 courses

Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.

Tailwind for Pentracor's CRP blood wash as therapy

Hennigsdorf, February 17, 2021 - Pentracor GmbH, based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), has achieved a major success with the publication of an article in the renowned immunology journal "Frontiers in Immunology". The title: "C-reactive protein activates cell death in poorly perfused cell tissue". The article, reviewed by the editors and several physicians at Frontiers, can be considered a milestone in the formation of opinion for clinical physicians on the new view of the physiological function of the protein CRP.

World's only CRP blood wash therapy now also successful for COVID-19

Hennigsdorf, January 27, 2021 - The medical technology company Pentracor GmbH, headquartered in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has successfully treated a patient suffering from COVID-19 caused by the Corona virus with its CE-certified and patent-protected medical product PentraSorb® CRP. The company has thus created another important option for action in the fight against the often fatal effects of the pandemic.

Ad hoc News

Publication of inside information in accordance with Article 17 MAR

Lecture on the topic of CRP apheresis in severe COVID-19 courses at the BioBilanz seminar

20.01.22

At the web seminar "Biotech vs. SARS-CoV-2: A BioBilanz", Pentracor gave a lecture on CRP apheresis against COVID-19. The field report was presented by Managing Director Dr. Ahmed Sheriff.

Pentracor passt Umsatzprognose für das Gesamtjahr 2021 an

(09.12.2021 / 14:37 CET/CEST) Pentracor GmbH, Schlagwort/e: Prognoseänderung

Hennigsdorf, 9. Dezember 2021 – Das Medizintechnikunternehmen Pentracor GmbH (Wandelanleihe ISIN: DE000A289XB9, WKN: A289XB) hat heute seine Umsatzprognose für das Gesamtjahr 2021 korrigiert. Die Gesellschaft geht nach aktueller Einschätzung nicht mehr davon aus, die geplanten Umsatzerlöse in Höhe von 2,0 Mio. Euro zu erreichen. Grund hierfür ist die pandemiebedingt reduzierte Investitionsbereitschaft …

Directors Dealings

Reporting and public disclosure of the transactions of persons discharging managerial responsibilities and persons closely associated with them in accordance with Art 19 MAR

 

Currently no announcements published in this section.